The Opioid REMS Template
This article was originally published in RPM Report
Executive Summary
Here is the final version of the Risk Evaluation & Mitigation Strategy FDA is imposing on two dozen sponsors of long-acting opioids. It was included in a letter to the sponsors sent April 19.